{
  "source": "PA-Notification-Emflaza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1218-8\nProgram Prior Authorization/Notification\nMedication Emflaza® (deflazacort)*\nP&T Approval Date 5/2017, 10/2018, 10/2019, 10/2020, 10/2021, 10/2022, 10/2023,\n10/2024\nEffective Date 1/1/2025\n1. Background:\nEmflaza (deflazacort)* is a corticosteroid indicated for the treatment of Duchenne muscular\ndystrophy (DMD) in patients 2 years of age and older.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Emflaza* will be approved based on the following criterion:\na. Diagnosis of Duchenne muscular dystrophy\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Emflaza* will be approved based on the following criterion:\na. Documentation of positive clinical response to Emflaza therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Emflaza is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer\nto plan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits, Medical Necessity and/or Step Therapy may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Emflaza [package insert]. Warren, NJ: PTC Therapeutics, Inc.; May 2024.\nProgram Prior Authorization/Notification - Emflaza (deflazacort)\nChange Control\n5/2017 New program.\n10/2018 Annual review. No changes to criteria. Updated reference.\n10/2019 Annual review. Updated background updating indication in patients 2\nyears and older. Updated reference.\n10/2020 Annual review. No",
    "2018 Annual review. No changes to criteria. Updated reference.\n10/2019 Annual review. Updated background updating indication in patients 2\nyears and older. Updated reference.\n10/2020 Annual review. No change to clinical criteria.\n10/2021 Annual review with no change to clinical criteria. Reference updated.\n10/2022 Annual review with no change to clinical criteria. Added state mandate\nfootnote.\n10/2023 Annual review with no changes to coverage criteria.\n10/2024 Annual review with no changes to coverage criteria. Added exclusion\nfootnote and updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}